Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 27 | 2023No Cell Therapy-Related Updates in April’s CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 26 | 2023Kymriah Sales Decrease; Prioritization of CAR-T Therapies for Immunology over LBCL and MM; Novartis Strategy for Contract Manufacturing; Novartis’s Q1 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Apr 24 | 2023No Cell Therapy-Related Updates in April’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA Apr 24 | 2023Thoughts on CARTITUDE-4’s EHA Abstract Being Prematurely Posted; Carvykti Demonstrates an Impressive Efficacy Profile in 2-4L MMAccess Free Blast
Free
Posted in: Allogeneic, Autologous Apr 21 | 2023Triumvira, Acepodia, and Arsenal Bio Present Their Innovative Technologies; AACR 2023 Analysis 5Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T Apr 21 | 2023UPDATED: Carvykti’s CARTITUDE-6 Trial to Initiate Ex-US Due to FDA Safety Requirements; LB2102 IND Clearance in SCLC; Legend H2 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD123 Apr 20 | 2023Caribou, AvenCell and Amgen Report Preclinical Data in AML; AACR 2023 Analysis 4Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Apr 19 | 2023Carvykti’s Revenue Increases +31% QoQ; Novartis to Manufacture Carvykti; JNJ Q1 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T Apr 19 | 2023AstraZeneca and Innovative Cellular Therapeutics Report Clinical Data in Solid Tumors; AACR 2023 Analysis 3Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Apr 18 | 2023Abecma’s Regulatory Applications for R/R MM Accepted in the US, Europe, and JapanAccess Free BlastFree
Posted in: Allogeneic, CAR-T Apr 18 | 2023Allogene Reports Updated Results from ALLO-316 in Renal Carcinoma; AACR 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, TCR Apr 17 | 2023CRISPR Tx, Adaptimmune, and Cellectis Report Data in Solid Tumors; AACR 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, TCR Apr 12 | 2023Adaptimmune and GSK Agree to Terms for PRAME and NY-ESO Programs Transfer; Kristin Yarema to Serve as Poseida’s President for Cell Therapy; Mythili Koneru Appointed as Legend’s CMOAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Apr 03 | 2023Carvykti’s CARTITUDE-6 Trial to Initiate Ex-US Due to FDA Safety Concerns; LB2102 IND Clearance in SCLC; Legend H2 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CD19 Mar 31 | 2023CHMP Adopts Positive Opinion for Breyanzi in 2L LBCL; When Could Abecma Receive a CHMP Positive Opinion for ≥3L MM? March CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD123 Mar 30 | 2023Arcellx and Gilead Focus on Accelerating CART-ddBCMA Clinical Development, Initiation of ACLX-002’s Ph1 trial in AML; Arcellx Q4 2022 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 27 | 2023Could Breyanzi Receive a CHMP Positive Opinion This Week? Abecma Starts EMA Assessment in ≥3L MM; March’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, TCR, Topics Mar 23 | 2023Strategic Combination of TCR2 Tx and Adaptimmune; Upcoming Clinical Updates for Gavo-cel and TC-510; TCR2 Tx Q4 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Mar 22 | 2023Francesco Marincola Departs Kite as Head of Cell Therapy Research; Yescarta Significantly Improved OS in 2L LBCLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Mar 17 | 2023Abecma’s sBLA Filing in ≥3L MM Remains on Track for Q1 2023; No Pipeline Updates; 2seventy bio Q4 2022 Earnings Summary; Gracell Acquires Patent Licenses from SeagenAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.